|
U.S. FDA Draft Guidance Lays Out Time Clock Strategies for PMAs, 510(k)s
The U.S. Food and Drug Administration (FDA) has released updated guidance describing how it intends to comply with submission review timelines set during user fee negotiations earlier this year.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives